3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Unknown
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
45
Neuroblastoma
16
Glioma
16
Brain Neoplasms
14
Astrocytoma
10
Neoplasms
8
Rhabdomyosarcoma
7
Sarcoma, Ewing
6
Recurrence
5
Oligodendroglioma
5
Medulloblastoma
5
Sarcoma
4
Osteosarcoma
4
Melanoma
4
Small Cell Lung Carcinoma
3
Neuroendocrine Tumors
3
Neuroectodermal Tumors, Primitive
3
Lymphoma
3
Gliosarcoma
3
Diffuse Intrinsic Pontine Glioma
3
Wilms Tumor
2
Rhabdoid Tumor
2
Pyloric Stenosis, Hypertrophic
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Ganglioneuroblastoma
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Interventions
Gemcitabine
54
130-nm albumin-bound paclitaxel
29
Magnetic Resonance Spectroscopy
21
Taxes
18
Fluorouracil
18
Specimen Handling
17
Oxaliplatin
17
Leucovorin
17
Drug Therapy
17
Albumin-Bound Paclitaxel
17
Irinotecan
14
pembrolizumab
13
Cyclophosphamide
11
Blood Specimen Collection
11
Biopsy
11
fludarabine
10
Radiosurgery
9
irinotecan sucrosofate
8
folfirinox
6
Magnetic Resonance Imaging
6
Cetuximab
6
Bevacizumab
6
dehydroftorafur
5
Surveys and Questionnaires
5
Nivolumab
5
Endoscopic Ultrasound-Guided Fine Needle Aspiration
5
sintilimab
4
olaparib
4
balstilimab
4
Surgical Procedures, Operative
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pancreatic Neoplasms
×
Temozolomide
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled